VACCINIA RECOMBINANT EXPRESSING LASSA-VIRUS INTERNAL NUCLEOCAPSID PROTEIN PROTECTS GUINEAPIGS AGAINST LASSA FEVER

J. C.S. Clegg*, Graham Lloyd

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)

Abstract

The Lister strain of vaccinia virus was used to construct a recombinant that expressed the nucleocapsid gene of Lassa virus. Guineapigs immunised with the recombinant virus were protected against challenge with Lassa virus, whereas control animals showed the usual disease course, including pyrexia, anorexia, viraemia, and death. These data indicate not only that protective immunity to Lassa fever can be evoked by an experimental vaccine, but also that this response can be mediated by an internal protein component of the virus.

Original languageEnglish
Pages (from-to)186-188
Number of pages3
JournalThe Lancet
Volume330
Issue number8552
DOIs
Publication statusPublished - 25 Jul 1987

Bibliographical note

Funding Information:
This work was supported by the Cancer Research Campaign and D. M. was a member of the Imperial Cancer Research Fund colorectal cancer unit. We thank Mrs Jane Wadsworth and Miss Sharon Love for assistance with the statistical analysis, Mr T. Jivraj for collection and analysis of the faecal samples, Miss J. Maybee for artwork, and Miss J. Grimsey for secretarial help.

Funding Information:
much advice and encouragement, and the Medical Research Council for support. Correspondence should be addressed to J. C.

Fingerprint

Dive into the research topics of 'VACCINIA RECOMBINANT EXPRESSING LASSA-VIRUS INTERNAL NUCLEOCAPSID PROTEIN PROTECTS GUINEAPIGS AGAINST LASSA FEVER'. Together they form a unique fingerprint.

Cite this